552 related articles for article (PubMed ID: 29017920)
1. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection.
Cho J; Yi H; Jang EY; Lee MS; Lee JY; Kang C; Lee CH; Kim K
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):298-304. PubMed ID: 29017920
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.
Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG
Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y
PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.
Kumaki Y; Day CW; Smee DF; Morrey JD; Barnard DL
Antiviral Res; 2011 Nov; 92(2):329-40. PubMed ID: 21925541
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
Haasbach E; Pauli EK; Spranger R; Mitzner D; Schubert U; Kircheis R; Planz O
Antiviral Res; 2011 Sep; 91(3):304-13. PubMed ID: 21777621
[TBL] [Abstract][Full Text] [Related]
7. CLEC5A-Mediated Enhancement of the Inflammatory Response in Myeloid Cells Contributes to Influenza Virus Pathogenicity In Vivo.
Teng O; Chen ST; Hsu TL; Sia SF; Cole S; Valkenburg SA; Hsu TY; Zheng JT; Tu W; Bruzzone R; Peiris JSM; Hsieh SL; Yen HL
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795434
[TBL] [Abstract][Full Text] [Related]
8. The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection.
Traboulsi H; Cloutier A; Boyapelly K; Bonin MA; Marsault É; Cantin AM; Richter MV
Antimicrob Agents Chemother; 2015 Oct; 59(10):6317-27. PubMed ID: 26248373
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
Kobayashi M; Kodama M; Noshi T; Yoshida R; Kanazu T; Nomura N; Soda K; Isoda N; Okamatsu M; Sakoda Y; Yamano Y; Sato A; Kida H
Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
[TBL] [Abstract][Full Text] [Related]
10. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
Kiso M; Ozawa M; Le MT; Imai H; Takahashi K; Kakugawa S; Noda T; Horimoto T; Kawaoka Y
J Virol; 2011 May; 85(10):4667-72. PubMed ID: 21367898
[TBL] [Abstract][Full Text] [Related]
11. 14-Deoxy-11,12-didehydroandrographolide attenuates excessive inflammatory responses and protects mice lethally challenged with highly pathogenic A(H5N1) influenza viruses.
Cai W; Chen S; Li Y; Zhang A; Zhou H; Chen H; Jin M
Antiviral Res; 2016 Sep; 133():95-105. PubMed ID: 27476045
[TBL] [Abstract][Full Text] [Related]
12. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus.
Zheng BJ; Chan KW; Lin YP; Zhao GY; Chan C; Zhang HJ; Chen HL; Wong SS; Lau SK; Woo PC; Chan KH; Jin DY; Yuen KY
Proc Natl Acad Sci U S A; 2008 Jun; 105(23):8091-6. PubMed ID: 18523003
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotides targeting the RNA binding region of the NP gene inhibit replication of highly pathogenic avian influenza virus H5N1.
Zhang T; Wang TC; Zhao PS; Liang M; Gao YW; Yang ST; Qin C; Wang CY; Xia XZ
Int Immunopharmacol; 2011 Dec; 11(12):2057-61. PubMed ID: 21933722
[TBL] [Abstract][Full Text] [Related]
14. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Hurt AC; Lowther S; Middleton D; Barr IG
Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
[TBL] [Abstract][Full Text] [Related]
15. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
Ilyushina NA; Hay A; Yilmaz N; Boon AC; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2008 Nov; 52(11):3889-97. PubMed ID: 18725448
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
Tomozawa T; Hoshino K; Yamashita M; Kubo S
J Infect Chemother; 2019 Aug; 25(8):584-588. PubMed ID: 30935767
[TBL] [Abstract][Full Text] [Related]
17. Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.
Marathe BM; Wong SS; Vogel P; Garcia-Alcalde F; Webster RG; Webby RJ; Najera I; Govorkova EA
Sci Rep; 2016 May; 6():26742. PubMed ID: 27221530
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.
Belser JA; Szretter KJ; Katz JM; Tumpey TM
Virology; 2013 Apr; 439(1):42-6. PubMed ID: 23453580
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection.
Taniguchi K; Ando Y; Kobayashi M; Toba S; Nobori H; Sanaki T; Noshi T; Kawai M; Yoshida R; Sato A; Shishido T; Naito A; Matsuno K; Okamatsu M; Sakoda Y; Kida H
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062315
[TBL] [Abstract][Full Text] [Related]
20. Pre-Treatment with Zirconia Nanoparticles Reduces Inflammation Induced by the Pathogenic H5N1 Influenza Virus.
Huo C; Xiao J; Xiao K; Zou S; Wang M; Qi P; Liu T; Hu Y
Int J Nanomedicine; 2020; 15():661-674. PubMed ID: 32099358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
